233 South 10th Street
Suite 332
Philadelphia, PA 19107
(215) 503-9259
(215) 503-9246 fax
Suite 332
Philadelphia, PA 19107
(215) 503-9259
(215) 503-9246 fax
Most Recent Peer-reviewed Publications
- Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
- Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
- Inflammatory signaling compromises cell responses to interferon alpha
- Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression
- Reply to A. Italiano
- Differential expression of arrestins is a predictor of breast cancer progression and survival
- Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma
- Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure
- Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer
- Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer
- PTP1B suppresses prolactin activation of Stat5 in breast cancer cells
- Protocol for constructing tissue arrays by cutting edge matrix assembly.
- Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation
- N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells
- Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling
- RB-pathway disruption in breast cancer: Differential association with disease subtypes, disease-specific prognosis and therapeutic response
- HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients
- Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence
- Prolactin inhibits BCL6 expression in breast cancer through a stat5a-dependent mechanism
- Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes